During the past decade, Gulf States Hemophilia and Thrombophilia Center conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 1 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gulf States Hemophilia and Thrombophilia Center" #1 sponsor was "American Thrombosis and Hemostasis Network" with 2 trials, followed by "Baxalta now part of Shire" with 1 trials sponsored, "Bioverativ, a Sanofi company" with 1 trials sponsored, "Tremeau Pharmceuticals, Inc." with 1 trials sponsored and "Weill Medical College of Cornell University" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gulf States Hemophilia and Thrombophilia Center" #1 collaborator was "BioMarin Pharmaceutical" with 1 trials as a collaborator, "CSL Behring" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Hemophilia of Georgia, Inc." with 1 trials as a collaborator and "Pfizer" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Gulf States Hemophilia and Thrombophilia Center" are "Hemophilia A" (2 trials), "Hemophilia B" (2 trials), "Bleeding Disorder" (1 trials), "Connective Tissue Disorder" (1 trials) and "Hematologic Disorder" (1 trials). Many other conditions were trialed in "Gulf States Hemophilia and Thrombophilia Center" in a lesser frequency.

Most popular intervention types in "Gulf States Hemophilia and Thrombophilia Center" are "Biological" (1 trials), "Drug" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Non-treatment, seroprevalence" (1 trials), "Placebo" (1 trials), "TRM-201 (Rofecoxib)" (1 trials) and "rFVIIIFc" (1 trials). Other intervention names were less common.

The vast majority of trials in "Gulf States Hemophilia and Thrombophilia Center" are 3 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Gulf States Hemophilia and Thrombophilia Center". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Gulf States Hemophilia and Thrombophilia Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Gulf States Hemophilia and Thrombophilia Center, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".